(0.34%) 5 117.05 points
(0.33%) 38 365 points
(0.38%) 15 989 points
(-0.97%) $83.04
(5.36%) $2.03
(0.35%) $2 355.40
(0.49%) $27.67
(4.13%) $960.15
(-0.26%) $0.932
(-0.44%) $10.98
(-0.56%) $0.796
(1.66%) $93.40
Live Chart Being Loaded With Signals
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma...
Stats | |
---|---|
本日の出来高 | 20 605.00 |
平均出来高 | 846 396 |
時価総額 | 8.53M |
EPS | $0 ( 2024-03-25 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.490 |
ATR14 | $0.00600 (1.66%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2013-11-04 | Austin Josiah T | Sell | 25 400 | Sponsored ADRs, each convertible into 25 ordinary shares |
2013-11-05 | Austin Josiah T | Sell | 23 922 | Sponsored ADRs, each convertible into 25 ordinary shares |
2013-10-25 | Austin Josiah T | Sell | 62 591 | Sponsored ADRs, each convertible into 25 ordinary shares |
2013-10-28 | Austin Josiah T | Sell | 37 409 | Sponsored ADRs, each convertible into 25 ordinary shares |
2013-10-29 | Austin Josiah T | Sell | 1 100 | Sponsored ADRs, each convertible into 25 ordinary shares |
INSIDER POWER |
---|
0.00 |
Last 100 transactions |
Buy: 5 568 614 | Sell: 243 947 |
ボリューム 相関
Kazia Therapeutics 相関
10 最も正の相関 | |
---|---|
PPTA | 0.912 |
ACAB | 0.901 |
OCAX | 0.901 |
AVAC | 0.898 |
EZGO | 0.897 |
ALSK | 0.894 |
ESCA | 0.891 |
KVSA | 0.888 |
BCOR | 0.883 |
CNGL | 0.882 |
10 最も負の相関 | |
---|---|
VORB | -0.908 |
PEAR | -0.899 |
VIEW | -0.897 |
CFBK | -0.888 |
GNOG | -0.887 |
JG | -0.882 |
BLU | -0.88 |
HRMY | -0.877 |
JAN | -0.877 |
CUTR | -0.872 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Kazia Therapeutics 相関 - 通貨/商品
Kazia Therapeutics 財務諸表
Annual | 2023 |
収益: | $555.00 |
総利益: | $555.00 (100.00 %) |
EPS: | $-1.120 |
FY | 2023 |
収益: | $555.00 |
総利益: | $555.00 (100.00 %) |
EPS: | $-1.120 |
FY | 2022 |
収益: | $25.00 |
総利益: | $25.00 (100.00 %) |
EPS: | $-1.860 |
FY | 2021 |
収益: | $15.18M |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.716 |
Financial Reports:
No articles found.
Kazia Therapeutics
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。